Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6502) 6502
Book Review (1915) 1915
Book / eBook (1426) 1426
Publication (610) 610
Book Chapter (49) 49
Conference Proceeding (20) 20
Dissertation (13) 13
Magazine Article (4) 4
Government Document (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6154) 6154
humans (5948) 5948
female (4136) 4136
cancer (3225) 3225
oncology (2809) 2809
middle aged (2637) 2637
aged (2245) 2245
male (2112) 2112
adult (2008) 2008
prognosis (1677) 1677
tumors (1521) 1521
pathology (1411) 1411
carcinoma (1244) 1244
carcinoma, ovarian epithelial (1235) 1235
animals (1219) 1219
ovarian cancer (1215) 1215
ovarian neoplasms - pathology (1086) 1086
diagnosis (1054) 1054
immunohistochemistry (1034) 1034
neoplasm staging (1029) 1029
neoplasms, glandular and epithelial - pathology (1026) 1026
aged, 80 and over (996) 996
research (928) 928
ovarian neoplasms - mortality (922) 922
neoplasms, glandular and epithelial - mortality (920) 920
surgery (891) 891
analysis (860) 860
neoplasms (848) 848
expression (826) 826
chemotherapy (777) 777
risk factors (756) 756
survival (737) 737
medicine & public health (733) 733
metastasis (729) 729
retrospective studies (711) 711
obstetrics & gynecology (667) 667
health aspects (664) 664
abridged index medicus (645) 645
care and treatment (641) 641
mice (596) 596
cell line, tumor (569) 569
medicine (556) 556
adenocarcinoma (549) 549
development and progression (549) 549
adenocarcinoma - pathology (543) 543
prostate cancer (539) 539
survival rate (533) 533
breast cancer (530) 530
therapy (498) 498
treatment outcome (494) 494
gene expression (480) 480
ovarian neoplasms - drug therapy (479) 479
disease-free survival (473) 473
kaplan-meier estimate (470) 470
neoplasms, glandular and epithelial - drug therapy (468) 468
survival analysis (464) 464
genetic aspects (462) 462
women (447) 447
gene expression regulation, neoplastic (439) 439
breast-cancer (436) 436
ovarian neoplasms - genetics (428) 428
article (427) 427
mortality (426) 426
biomarkers, tumor - metabolism (424) 424
diseases (419) 419
cell biology (418) 418
young adult (400) 400
neoplasms, glandular and epithelial - genetics (398) 398
proteins (397) 397
risk (394) 394
adolescent (383) 383
cells (379) 379
disease progression (372) 372
neoplasms, glandular and epithelial - surgery (364) 364
prostatic neoplasms - pathology (362) 362
hematology, oncology and palliative medicine (350) 350
biomarkers, tumor - analysis (349) 349
oncology, experimental (348) 348
ovarian neoplasms - metabolism (345) 345
medical prognosis (344) 344
ovarian neoplasms - surgery (343) 343
cancer research (340) 340
follow-up studies (330) 330
neoplasm invasiveness (327) 327
carcinogenesis (323) 323
neoplasms, glandular and epithelial - metabolism (323) 323
proportional hazards models (323) 323
epithelial ovarian cancer (318) 318
research article (315) 315
apoptosis (312) 312
biomarkers (308) 308
biopsy (302) 302
stomach neoplasms - pathology (301) 301
mutation (294) 294
gastroenterology & hepatology (289) 289
breast neoplasms - pathology (284) 284
obstetrics and gynecology (276) 276
neoplasm metastasis (274) 274
epidemiology (272) 272
biomarkers, tumor - genetics (271) 271
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (1191) 1191
Collection Dvlpm't (Acquisitions) - Closed Orders (55) 55
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (38) 38
UTL at Downsview - May be requested (32) 32
Collection Dvlpm't (Acquisitions) - Vendor file (27) 27
Scarborough Hospital - General (14) 14
Humber River Regional Hospital - Finch Stacks (11) 11
Scarborough Hospital - Birchmount (11) 11
St. Michael's Hospital - Stacks (11) 11
Markham Stouffville Hospital - Stacks (10) 10
UofT at Mississauga - Stacks (10) 10
Dentistry (Harry R Abbott) - Stacks (9) 9
Gerstein Science - Circulation Desk (9) 9
Online Resources - Online (9) 9
Credit Valley Hospital - Stacks (8) 8
Mt Sinai Hospital - Pathology (8) 8
Humber River Regional Hospital - Church Stacks (7) 7
Lakeridge Health Sciences - Oshawa (7) 7
Providence Healthcare - Reference (5) 5
Providence Healthcare - Stacks (4) 4
UofT at Scarborough - Stacks (4) 4
Women's College Hospital - Stacks (4) 4
Dentistry (Harry R Abbott) - Withdrawn (3) 3
Gerstein Science - Reference (3) 3
St Josephs Health Centre - Stacks (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
Toronto East General Hospital - Stacks (3) 3
West Park Healthcare Centre - Stacks (3) 3
Chemistry (A D Allen) - Stacks (2) 2
Credit Valley Hospital - Reference (2) 2
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (2) 2
New College (Ivey) - Stacks (2) 2
Scarborough Hospital - Hospital Department (2) 2
St. Michael's Hospital - Circulation Desk (2) 2
Trillium Health Centre - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Credit Valley Hospital - Special Collections (1) 1
Dentistry (Harry R Abbott) - Circulation Desk (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Faculty of Information - Subject Analysis Systems (1) 1
Gerstein Science - Cancelled Order (1) 1
Gerstein Science - Not Returned (1) 1
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Humber River Regional Hospital - Church Reference (1) 1
Markham Stouffville Hospital - Storage (1) 1
Providence Healthcare - Withdrawn (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
Toronto East General Hospital - Missing (1) 1
Toronto East General Hospital - Online (1) 1
UofT Schools - Stacks (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Mississauga - Reference (1) 1
Victoria University Emmanuel College - Birge Storage (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7910) 7910
German (33) 33
Spanish (31) 31
Chinese (18) 18
French (13) 13
Japanese (5) 5
Italian (4) 4
Polish (4) 4
Turkish (4) 4
Hungarian (3) 3
Russian (3) 3
Arabic (2) 2
Danish (2) 2
Dutch (2) 2
Czech (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
by van Driel, Willemien J and Koole, Simone N and Sikorska, Karolina and Schagen van Leeuwen, Jules H and Schreuder, Henk W.R and Hermans, Ralph H.M and de Hingh, Ignace H.J.T and van der Velden, Jacobus and Arts, Henriëtte J and Massuger, Leon F.A.G and Aalbers, Arend G.J and Verwaal, Victor J and Kieffer, Jacobien M and Van de Vijver, Koen K and van Tinteren, Harm and Aaronson, Neil K and Sonke, Gabe S
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 3, pp. 230 - 240
The addition of HIPEC with cisplatin to cytoreductive surgery in stage III ovarian cancer resulted in recurrence-free survival that was longer by 3.5 months... 
GYNECOLOGIC-ONCOLOGY | TRIAL | MEDICINE, GENERAL & INTERNAL | CYTOREDUCTIVE SURGERY | NEOADJUVANT CHEMOTHERAPY | CISPLATIN | PHARMACOKINETICS | PERITONEAL CARCINOMATOSIS | OUTCOMES | Humans | Middle Aged | Carboplatin - administration & dosage | Combined Modality Therapy | Ovarian Neoplasms - mortality | Cytoreduction Surgical Procedures | Neoplasms, Glandular and Epithelial - surgery | Cisplatin - administration & dosage | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hyperthermia, Induced | Intention to Treat Analysis | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Carcinoma, Ovarian Epithelial | Female | Aged | Neoplasm Staging | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Hyperthermic intraperitoneal chemotherapy | Cancer patients | Care and treatment | Usage | Ovarian cancer | Clinical trials | Oncology | Patients | Survival | Cisplatin | Cancer surgery | Side effects | Chemotherapy | Womens health | Surgery | Paclitaxel | Carboplatin | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
by Katsumata, Noriyuki, Prof and Yasuda, Makoto, Prof and Isonishi, Seiji, Prof and Takahashi, Fumiaki, PhD and Michimae, Hirofumi, PhD and Kimura, Eizo, MD and Aoki, Daisuke, Prof and Jobo, Toshiko, MD and Kodama, Shoji, MD and Terauchi, Fumitoshi, Prof and Sugiyama, Toru, Prof and Ochiai, Kazunori, Prof and Japanese Gynecologic Oncology Grp and Japanese Gynecologic Oncology Group
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 1020 - 1026
Summary Background The primary analysis of the JGOG 3016 trial showed that a dose-dense paclitaxel and carboplatin regimen significantly improves... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | INTERGROUP | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Humans | Ovarian Neoplasms - pathology | Proportional Hazards Models | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Ovarian Neoplasms - mortality | Peritoneal Neoplasms - mortality | Disease-Free Survival | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - mortality | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Female | Neoplasm Staging | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
by Spiliotis, J and Halkia, E and Lianos, E and Kalantzi, N and Grivas, A and Efstathiou, E and Giassas, S
Annals of Surgical Oncology, ISSN 1068-9265, 05/2015, Volume 22, Issue 5, pp. 1570 - 1575
The current treatment of ovarian cancer consists of cytoreductive surgery (CRS) and systemic chemotherapy. The aim of this study was to examine if hyperthermic... 
SURVIVAL | SURGERY | MULTICENTER | MANAGEMENT | ONCOLOGY | HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY | CARCINOMA | Cytoreduction Surgical Procedures - mortality | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Neoplasms, Glandular and Epithelial - mortality | Female | Peritoneal Neoplasms - secondary | Neoplasms, Glandular and Epithelial - pathology | Neoplasm Invasiveness | Neoplasm Recurrence, Local - therapy | Injections, Intraperitoneal | Neoplasms, Glandular and Epithelial - therapy | Survival Rate | Combined Modality Therapy | Lymphatic Metastasis | Peritoneal Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Ovarian Epithelial | Ovarian Neoplasms - therapy | Hyperthermia, Induced - mortality | Neoplasm Staging | Peritoneal Neoplasms - therapy | Relapse | Chemotherapy | Oncology, Experimental | Research | Cancer | Diseases | Ovarian cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
by Liu, Joyce F, Dr and Barry, William T, PhD and Birrer, Michael, MD and Lee, Jung-Min, MD and Buckanovich, Ronald J, MD and Fleming, Gini F, Prof and Rimel, BJ, MD and Buss, Mary K, MD and Nattam, Sreenivasa, MD and Hurteau, Jean, MD and Luo, Weixiu, MS and Quy, Philippa, MA and Whalen, Christin, BSN and Obermayer, Lisa, BA and Lee, Hang, PhD and Winer, Eric P, Prof and Kohn, Elise C, MD and Ivy, S Percy, MD and Matulonis, Ursula A, MD
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1207 - 1214
Summary Background Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1,... 
Hematology, Oncology and Palliative Medicine | TRIAL | POLY(ADP-RIBOSE) POLYMERASE | ONCOLOGY | BEVACIZUMAB | DOWN-REGULATION | FALLOPIAN-TUBE | OPEN-LABEL | EPITHELIAL OVARIAN | MAINTENANCE THERAPY | PRIMARY PERITONEAL | NEGATIVE BREAST-CANCER | Piperazines - administration & dosage | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Neoplasms, Glandular and Epithelial - mortality | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Risk Assessment | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Carcinoma, Ovarian Epithelial | Aged | Women | Antimitotic agents | Relapse | Oncology, Experimental | Research | Antineoplastic agents | Vascular endothelial growth factor | Sugars | Cancer | Diseases | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Ten-Year Relative Survival for Epithelial Ovarian Cancer
by Baldwin, Lauren A and Huang, Bin and Miller, Rachel W and Tucker, Thomas and Goodrich, Scott T and Podzielinski, Iwona and DeSimone, Christopher P and Ueland, Fred R and van Nagell, John R and Seamon, Leigh G
Obstetrics & Gynecology, ISSN 0029-7844, 09/2012, Volume 120, Issue 3, pp. 612 - 618
OBJECTIVE:Most patients with epithelial ovarian cancer who are alive at 5 years have active disease. Thus, 10-year survival rather than 5-year survival may be... 
SURGERY | TRIAL | CARBOPLATIN | CISPLATIN | STAGE-III | PACLITAXEL | OBSTETRICS & GYNECOLOGY | Neoplasms, Glandular and Epithelial - pathology | United States - epidemiology | SEER Program | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasms, Glandular and Epithelial - therapy | Ovarian Neoplasms - pathology | Neoplasms, Glandular and Epithelial - ethnology | Survival Rate | Life Tables | Ovarian Neoplasms - mortality | Ovarian Neoplasms - ethnology | Neoplasms, Glandular and Epithelial - mortality | Aged, 80 and over | Carcinoma, Ovarian Epithelial | Ovarian Neoplasms - therapy | Adult | Female | Aged | Neoplasm Staging | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
by Burger, Robert A and Brady, Mark F and Bookman, Michael A and Fleming, Gini F and Monk, Bradley J and Huang, Helen and Mannel, Robert S and Homesley, Howard D and Fowler, Jeffrey and Greer, Benjamin E and Boente, Matthew and Birrer, Michael J and Liang, Sharon X and Gynecologic Oncology Grp and Gynecologic Oncology Group
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 26, pp. 2473 - 2483
Incorporating bevacizumab in a chemotherapy regimen (7.5 mg/kg every 3 weeks for five or six cycles) and then continuing bevacizumab alone for a total of 12... 
ANTIANGIOGENIC THERAPY | MEDICINE, GENERAL & INTERNAL | ASCITES | SOLID TUMORS | FACTOR EXPRESSION | PHASE-II | MONOCLONAL-ANTIBODY | PROGNOSTIC-SIGNIFICANCE | TUMOR ANGIOGENESIS | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ovarian Neoplasms - mortality | Bevacizumab | Young Adult | Neoplasms, Glandular and Epithelial - mortality | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carboplatin - administration & dosage | Combined Modality Therapy | Neoplasms, Glandular and Epithelial - surgery | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Carcinoma, Ovarian Epithelial | Quality of Life | Aged | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Intravenous administration | Body weight | Cancer therapies | Survival | Patients | Angiogenesis | Chemotherapy | Surgery | Paclitaxel | Monoclonal antibodies | Carboplatin | Vascular endothelial growth factor | Cancer | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A Phase 3 Trial of Bevacizumab in Ovarian Cancer
by Perren, Timothy J and Swart, Ann Marie and Pfisterer, Jacobus and Ledermann, Jonathan A and Pujade-Lauraine, Eric and Kristensen, Gunnar and Carey, Mark S and Beale, Philip and Cervantes, Andrés and Kurzeder, Christian and Bois, Andreas du and Sehouli, Jalid and Kimmig, Rainer and Stähle, Anne and Collinson, Fiona and Essapen, Sharadah and Gourley, Charlie and Lortholary, Alain and Selle, Frédéric and Mirza, Mansoor R and Leminen, Arto and Plante, Marie and Stark, Dan and Qian, Wendi and Parmar, Mahesh K.B and Oza, Amit M and ICON7 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 26, pp. 2484 - 2496
The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of... 
CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | SOLID TUMORS | ANGIOGENESIS | CYCLOPHOSPHAMIDE | EXPRESSION | INTRAPERITONEAL CISPLATIN | III TRIAL | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Combined Modality Therapy | Ovarian Neoplasms - mortality | Neoplasms, Glandular and Epithelial - surgery | Bevacizumab | Disease-Free Survival | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Ovarian Epithelial | Quality of Life | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Risk groups | Body weight | Clinical trials | Survival | Angiogenesis | Chemotherapy | Womens health | Paclitaxel | Carboplatin | Vascular endothelial growth factor | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer
by Hu, Zhongyi and Hu, Xiaowen and Feng, Yi and Zhang, Youyou and Zhang, Lin and Zhang, Dongmei and Zhao, Sihai D and Greshock, Joel and Yang, Lu and Zhong, Xiaomin and Wang, Li-Ping and Jean, Stephanie and Li, Hongzhe and Li, Chunsheng and Huang, Qihong and Katsaros, Dionyssios and Montone, Kathleen T and Tanyi, Janos L and Lu, Yiling and Boyd, Jeff and Nathanson, Katherine L and Mills, Gordon B
Cancer Cell, ISSN 1535-6108, 09/2014, Volume 26, Issue 3, pp. 344 - 357
In a genome-wide survey on somatic copy-number alterations (SCNAs) of long noncoding RNA (lncRNA) in 2,394 tumor specimens from 12 cancer types, we found that... 
GENE ACTIVATION PROGRAMS | MESSENGER-RNAS | METASTASIS | EVOLUTION | ONCOLOGY | HUMAN-CELLS | PROSTATE-CANCER | XIST RNA | TRANSCRIPTION | COPY-NUMBER ALTERATION | ENHANCERS | CELL BIOLOGY | Neoplasm Transplantation | Polycomb Repressive Complex 1 - metabolism | Genomics | Humans | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Transcriptome | Neoplasms, Glandular and Epithelial - metabolism | Ovarian Neoplasms - mortality | RNA, Long Noncoding - physiology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Cyclin-Dependent Kinase Inhibitor p21 - genetics | Neoplasms, Glandular and Epithelial - mortality | RNA Interference | Cellular Senescence | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Female | Ovarian Neoplasms - metabolism | Protein Stability | Oncogenes | Neoplasms, Glandular and Epithelial - pathology | Gene Expression | Kaplan-Meier Estimate | Tumor Burden | Animals | Mice, Nude | Cell Line, Tumor | Mice | Polymorphism, Single Nucleotide | Women | Epigenetic inheritance | Medical colleges | Analysis | Genetic research | Antisense RNA | Health aspects | Cancer | Ovarian cancer | Genetic transcription | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
by Robert A. Burger and Michael W. Sill and Bradley J. Monk and Benjamin E. Greer and Joel I. Sorosky
Journal of Clinical Oncology, ISSN 0732-183X, 11/2007, Volume 25, Issue 33, pp. 5165 - 5171
Purpose Vascular endothelial growth factor (VEGF) seems to be a promoter of tumor progression for epithelial ovarian cancer (EOC) and primary peritoneal cancer... 
THERAPY | ASCITES | ONCOLOGY | COLORECTAL-CANCER | VEGF | GUIDELINES | GROUP ECOG | TUMOR ANGIOGENESIS | CARCINOMA | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Neoplasm Recurrence, Local - mortality | Peritoneal Neoplasms - mortality | Bevacizumab | Antibodies, Monoclonal, Humanized | Peritoneal Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - mortality | Adolescent | Neoplasms, Glandular and Epithelial - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Aged | Ovarian Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer
by Duraiswamy, Jaikumar and Freeman, Gordon J and Coukos, George
Cancer Research, ISSN 0008-5472, 12/2013, Volume 73, Issue 23, pp. 6900 - 6912
The tumor microenvironment mediates induction of the immunosuppressive programmed cell death-1 (PD-1) pathway, and targeted interventions against this pathway... 
ACTIVATION | DENDRITIC CELLS | ONCOLOGY | GM-CSF | TOLERANCE | IN-VIVO | REGULATORY T